<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Exosomes in Tissue Engineering and Regenerative Medicine: Unlocking their Therapeutic Potential as Biological Nanocarriers</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>1993</FirstPage>
			<LastPage>1995</LastPage>
			<ELocationID EIdType="pii">247315</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2026.247315</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mehrdad</FirstName>
					<LastName>Moosazadeh Moghaddam</LastName>
<Affiliation>Tissue Engineering and Regenerative Medicine Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-4645-8661</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>21</Day>
				</PubDate>
			</History>
		<Abstract></Abstract>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247315_b7d1c343a60417453ed5834d6954b9c8.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>A Promising Approach for Pancreatic Cancer Therapy: Integrating Artificial Intelligence, Oncolytic Virotherapy, Probiotic Therapy, Stem Cell Therapy, and Immunotherapy</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>1996</FirstPage>
			<LastPage>1998</LastPage>
			<ELocationID EIdType="pii">247320</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.554319.1930</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Piruz</FirstName>
					<LastName>Shadbash</LastName>

						<AffiliationInfo>
						<Affiliation>Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and
Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti
University, Tehran, Iran</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0009-0008-1328-482X</Identifier>

</Author>
<Author>
					<FirstName>Marzieh</FirstName>
					<LastName>Bahari Babadi</LastName>
<Affiliation>Department of Biochemistry, Medical School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</Affiliation>
<Identifier Source="ORCID">0009-0002-9280-389X</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>10</Month>
					<Day>19</Day>
				</PubDate>
			</History>
		<Abstract>&lt;br&gt;&lt;br&gt;</Abstract>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247320_0121a6df0843ebca678dce97be2b6ac1.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Antibacterial Behavior of Oxygen-Generating Nanomaterial for Medical Applications</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>1999</FirstPage>
			<LastPage>2008</LastPage>
			<ELocationID EIdType="pii">247330</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.560642.1949</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mehdi</FirstName>
					<LastName>Faraji</LastName>
<Affiliation>Oral and Maxillofacial Surgery Resident, Craniomaxillofacial Research Center, Oral and Maxillofacial Surgery Department,
School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-6287-6831</Identifier>

</Author>
<Author>
					<FirstName>Fatemeh</FirstName>
					<LastName>Mohammadzadeh</LastName>

						<AffiliationInfo>
						<Affiliation>Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0000-0001-6287-6831</Identifier>

</Author>
<Author>
					<FirstName>Kimia</FirstName>
					<LastName>Sanjabi</LastName>

						<AffiliationInfo>
						<Affiliation>Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0000-0001-6287-6831</Identifier>

</Author>
<Author>
					<FirstName>Mohadese</FirstName>
					<LastName>Saraei</LastName>

						<AffiliationInfo>
						<Affiliation>Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0009-0001-2065-7283</Identifier>

</Author>
<Author>
					<FirstName>Mazaher</FirstName>
					<LastName>Gholipourmalekabadi</LastName>

						<AffiliationInfo>
						<Affiliation>Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Nanobiotechnology &amp; Regenerative Medicine Innovation Group, Noavarn Salamat Zhino (Zhinohealth), Tehran, Iran</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0000-0001-6287-6831</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>11</Month>
					<Day>21</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;There are significant challenges for the development of an efficient antibacterial agent for the prevention or treatment of post-surgical infections, especially with synthetic scaffolds for surgical implants. This problem has been further exacerbated by the extensive use of antibiotics in healthcare settings, which has led to an increased incidence of multidrug-resistant bacteria. Despite several successes in developing novel antibacterial agents, there are ongoing efforts to find effective and safe ones. Recently, the development of oxygen-generating nanomaterials has been proposed as a promising approach for antibacterial applications. The preliminary investigation demonstrated that such materials could exhibit strong antibacterial activity, minimize postsurgery-induced hypoxia, and prevent infections. Regenerative medicine is a multibillion-dollar industry, and the lack of suitable materials, such as 3D scaffolds, has hindered its application in clinical settings. A critical review of the different kinds of oxygen-generating reagents, as well as their mechanisms of oxygen release and antimicrobial potential, is presented, following an appraisal of the literature.&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Antibacterial agents</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Nosocomial infections</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Post-Surgical Infections</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Oxygen-Generating Biomaterials</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247330_857d16a4780d7bef0476c840d0658c75.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Plant Antimicrobial Peptides: Bioinformatics Approaches for Discovery, Characterization, and Functional Insights</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2009</FirstPage>
			<LastPage>2023</LastPage>
			<ELocationID EIdType="pii">247331</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.542257.1907</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Anahita</FirstName>
					<LastName>Panji</LastName>
<Affiliation>Department of Plant Production and Genetic Engineering, Faculty of Agriculture, Lorestan University, Khorramabad, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-7137-5366</Identifier>

</Author>
<Author>
					<FirstName>Ahmad</FirstName>
					<LastName>Ismaili</LastName>
<Affiliation>Department of Plant Production and Genetic Engineering, Faculty of Agriculture, Lorestan University, Khorramabad, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-8718-3943</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>08</Month>
					<Day>23</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;Plant antimicrobial peptides (AMPs) are small, naturally occurring biomolecules that play crucial roles in the plant innate immune system. Their structural diversity, cationic nature, and stability under adverse conditions enable them to act effectively against a broad spectrum of pathogens, including fungi, bacteria, and viruses. Beyond biotic defense, AMPs also contribute to tolerance against abiotic stresses such as drought, salinity, and ultraviolet radiation. This review integrates findings from peer-reviewed studies and biological databases focusing on plant AMPs, with an emphasis on bioinformatics tools and computational approaches. Both conventional sequence-based analyses (e.g., BLAST, HMMER) and recent advances in machine learning and structural modeling (e.g., Deep-AmPEP, AlphaFold) were assessed to illustrate their role in AMP discovery and functional characterization. Comparative analyses reveal the evolution of bioinformatics methodologies and their successful application in crop species for large-scale AMP identification and &lt;em&gt;in silico&lt;/em&gt; characterization. Case studies demonstrate how integrative computational pipelines can accelerate AMP discovery and provide practical insights for agricultural improvement. Additionally, the review highlights the potential for developing a comprehensive Iranian plant AMP database and species-specific predictive models to facilitate regional research. Plant AMPs represent promising molecules for biotechnology, agriculture, and pharmaceuticals. The integration of computational prediction, genetic engineering, and applied research will accelerate their use in crop improvement and therapeutic development. Future studies focusing on database expansion and machine learning applications are expected to further enhance our understanding and utilization of plant-derived AMPs.&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Antimicrobial Peptides</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Bioinformatics</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Machine Learning</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">In Silico Prediction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Bioinformatics Pipelines</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Database Development</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247331_a4abd68f0ec37afb17ed2efbe20c9220.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Dual Use of Emerging Biotechnologies: Governance and Biosecurity Challenges in the New Era</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2024</FirstPage>
			<LastPage>2034</LastPage>
			<ELocationID EIdType="pii">247336</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.533238.1889</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mohammad Ebrahim</FirstName>
					<LastName>Minaei</LastName>
<Affiliation>Faculty of Basic Science, Imam Hossein Comprehension University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5087-891X</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>07</Month>
					<Day>08</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle2&quot;&gt;Emerging biotechnologies hold great promise but also pose risks from accidental or deliberate misuse. Assessing these threats requires a systematic approach to examine potential dangers and plan for future developments. Effective biosecurity policies demand an understanding of current biotechnological capabilities and anticipation of their evolution. &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;This qualitative thematic review analyzes biosecurity threats from emerging biotechnologies reported in the scientific literature between 2014-2024. We conducted comprehensive literature searches in PubMed, Scopus, and Google Scholar using terms related to core biotechnologies (e.g., &quot;synthetic biology,&quot; &quot;gene editing&quot;) and threat concepts (e.g., &quot;biosecurity,&quot; &quot;dual-use&quot;). Relevant publications were analyzed to identify and synthesize recurring themes and governance challenges. &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The analysis identified dual-use potential as the most prominent biosecurity concern associated with emerging biotechnologies. The review synthesizes the literature to critically evaluate key threats, including biological weapons, environmental impacts, and governance challenges. It further discusses how national and global biosecurity policies can be adapted to maximize the benefits of these technologies while minimizing risks. &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Establishing governance policies to bridge the gap between the security of previous-generation biotechnology and the scientific and technological capabilities of the next decade’s emerging biotechnologies, as well as to maximize the benefits of deploying and minimize the potential for dual use of emerging biotechnologies, is essential to address the challenges and concerns associated with emerging biotechnologies&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Biosecurity</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Emerging Biotechnologies</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Dual Use</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Governance</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Biological Agents</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247336_9566ac69b9374f6cdfc67b1628af8699.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Tyrosinase Inhibitory Activity of Black Soldier Fly (Hermetia illucens) Larval Hydrolysate</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2035</FirstPage>
			<LastPage>2043</LastPage>
			<ELocationID EIdType="pii">247493</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.531906.1888</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Hegar</FirstName>
					<LastName>Pramastya</LastName>
<Affiliation>Department of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia</Affiliation>
<Identifier Source="ORCID">0000-0002-4585-219X</Identifier>

</Author>
<Author>
					<FirstName>Felix Saccio</FirstName>
					<LastName>Teng</LastName>
<Affiliation>Department of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia</Affiliation>
<Identifier Source="ORCID">0009-0007-1875-8409</Identifier>

</Author>
<Author>
					<FirstName>Defri</FirstName>
					<LastName>Rizaldy</LastName>
<Affiliation>Department of Pharmaceutical Biology, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia</Affiliation>
<Identifier Source="ORCID">0000-0001-9745-3855</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>07</Month>
					<Day>02</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Black Soldier Fly (BSF) (&lt;/span&gt;&lt;em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Hermetia illucens&lt;/span&gt;&lt;/em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;) larvae contain protein in varying amounts depending on the age at harvest. Due to their high protein content, BSF larvae represent a promising alternative protein source with potential bioactivities, including tyrosinase inhibitory activity. This study aimed to evaluate the tyrosinase inhibitory activity of BSF larval protein hydrolysates as a function of larval age and the fractionation process.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Materials and Methods:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The larvae were dried and defatted using the Soxhlet extraction method. The defatted larvae were characterized by determining ash, moisture, and soluble protein contents. Enzymatic hydrolysis was carried out using Alcalase&lt;/span&gt;&lt;sup&gt;&lt;span class=&quot;fontstyle3&quot;&gt;Ⓡ&lt;/span&gt;&lt;/sup&gt;&lt;span class=&quot;fontstyle2&quot;&gt;. Soluble protein content in the hydrolysates was analyzed using the Bradford assay. The degree of hydrolysis (DH) of the hydrolysates was analyzed using the o-phthaldialdehyde (OPA) method. The hydrolysates were then freeze-dried and fractionated using C18 Solid Phase Extraction (SPE) before tyrosinase inhibition assays.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Results:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The highest tyrosinase inhibitory activity among the samples was observed in the 15-day-old (D15 larvae) hydrolysate at a concentration of 40,000 ppm, showing 88.98% inhibition. In comparison, inhibition at the same concentration was 75.77% for 5-day-old (D5 larvae), 82.07% for 10-day-old (D10 larvae), and 87.78% for 13-day-old (D13 larvae) hydrolysates.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;BSF larval protein hydrolysates exhibit varying levels of soluble protein depending on larval age. Moreover, the C18 SPE fractionation process yielded a higher percentage and more uniformity of tyrosinase inhibition than the unfractionated sample.&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Hermetia Illucens</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Tyrosinase Inhibition</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Enzymatic hydrolysis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Solid-phase extraction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Larval Hydrolysate</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Alcalase</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247493_972a01ec512700c3c8d7e766937057cc.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>In vitro Effects of Acetaldehyde and Cotinine on Proliferation and Secretory Activity of Rat Umbilical Cord-Derived Mesenchymal Stem Cells</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2044</FirstPage>
			<LastPage>2051</LastPage>
			<ELocationID EIdType="pii">247513</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2026.581981.2006</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Ghassan Khudhair</FirstName>
					<LastName>Esmael</LastName>
<Affiliation>College of Veterinary Medicine, University of Al-Qadisiyah, Qadisiyah, Iraq</Affiliation>
<Identifier Source="ORCID">0000-0002-3440-9205</Identifier>

</Author>
<Author>
					<FirstName>Noor Mahmood</FirstName>
					<LastName>Majeed</LastName>
<Affiliation>Branch of Basic Sciences, College of Dentistry, University of Al-Qadisiyah, Qadisiyah, Iraq</Affiliation>
<Identifier Source="ORCID">0009-0002-1820-9307</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>05</Month>
					<Day>17</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Umbilical cord–derived mesenchymal stem cells (UCMSCs) are widely utilized in regenerative medicine owing to their proliferative and secretory capabilities. However, the effects of alcohol- and tobacco-derived metabolites, specifically acetaldehyde and cotinine, on UCMSC viability and function remain poorly understood. This study aimed to compare the cytotoxic and secretory responses of rat UCMSCs following &lt;em&gt;in vitro&lt;/em&gt; exposure to acetaldehyde and cotinine.&lt;/span&gt;&lt;br&gt;&lt;strong&gt;&lt;span class=&quot;fontstyle0&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Rat UCMSCs were cultured in DMEM/F12 and seeded at 5&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;×&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;10&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;⁵ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;cells per T-25 flask. A total of 40 flasks were allocated to three groups: acetaldehyde (30 µM, n = 15), cotinine (14 µM, n = 15), and untreated controls (n = 10). Cells were incubated for 5 days under standard conditions. Cell counts were recorded daily, and the levels of VEGF, HGF, IGF-1, SDF-1/CXCL12, IL-6, TNF-&lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;α&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;, and IL-1&lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;β &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;were quantified using a multiplex immunoassay. Statistical analysis was performed using two-way ANOVA.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Results:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Acetaldehyde exposure resulted in a progressive decline in UCMSC numbers from 4.8&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;×&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;10&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;⁵ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;to 2.8&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;×&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;10&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;⁵ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;over 5 days, whereas cotinine increased cell numbers from 5.4&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;×&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;10&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;⁵ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;to 9.0&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;×&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;10&lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;⁵&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;. Acetaldehyde induced an early peak, followed by subsequent declines in VEGF, HGF, IGF-1, SDF-1/CXCL12, and IL-6, while TNF-&lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;α &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;and IL-1&lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;β &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;showed variable patterns. In contrast, cotinine led to significantly less expansion compared with untreated controls, although it did induce a modest increase from baseline.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Acetaldehyde exerts a markedly more pronounced cytotoxic and suppressive effect on rat UCMSCs compared with cotinine, which induces a gradual increase in cell proliferation and secretory activity. However, cotinine&#039;s effect is less inhibitory than acetaldehyde, yet it still significantly reduces expansion relative to untreated cells. These findings underscore the differential biological impacts of alcohol- and tobacco-related metabolites on stem cell function &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;in vitro&lt;/em&gt;.&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Mesenchymal Stem Cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Umbilical cord</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Acetaldehyde</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">cotinine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cell proliferation</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cytokines</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247513_b7cb37564952f8595d6da0fb595c4898.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Development and Characterization of Niosomal Nanoparticles for Simultaneous Co-Delivery of Tamoxifen and Curcumin in Breast Cancer Therapy</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2052</FirstPage>
			<LastPage>2060</LastPage>
			<ELocationID EIdType="pii">247498</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.548971.1920</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Seyedhamidreza</FirstName>
					<LastName>Emadiyanrazavi</LastName>
<Affiliation>Department of Biomedical Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0009-0009-2328-3932</Identifier>

</Author>
<Author>
					<FirstName>Mehdi</FirstName>
					<LastName>Kamali</LastName>
<Affiliation>Department of Biotechnology, Faculty of Biological Science and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5665-5303</Identifier>

</Author>
<Author>
					<FirstName>Mohammad Hasan</FirstName>
					<LastName>Darvishi</LastName>
<Affiliation>Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5702-3332</Identifier>

</Author>
<Author>
					<FirstName>Hamidreza</FirstName>
					<LastName>Javadi</LastName>
<Affiliation>Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>09</Month>
					<Day>24</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Breast cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality worldwide. Although chemotherapeutic agents such as tamoxifen are widely employed, their therapeutic efficacy is often limited by poor bioavailability and adverse side effects. Combining tamoxifen with curcumin, a natural polyphenolic compound with well-documented anticancer potential, may enhance treatment outcomes through synergistic interactions. However, the clinical application of both agents is restricted due to issues such as low solubility and rapid degradation. To address these challenges, niosomal nanoparticles were designed and evaluated for the codelivery of tamoxifen and curcumin.&lt;/span&gt;&lt;br&gt;&lt;strong&gt;&lt;span class=&quot;fontstyle0&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span class=&quot;fontstyle2&quot;&gt;To fabricate niosomal nanoparticles, various surfactants (Span 20, Span 60, and Span 80) in combination with cholesterol were used to optimize particle size, stability, and encapsulation efficiency. The formulations were characterized for morphology, particle size distribution, zeta potential, and drug loading capacity using dynamic light scattering (DLS) and scanning electron microscopy (SEM). Additionally, &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;in vitro&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;drug release studies were performed under physiological (pH 7.4) and acidic (pH 5) conditions to simulate the tumor microenvironment. Cytotoxicity of the formulations was assessed using MCF-7 breast cancer cells and HEK-293 normal cells via the MTT Assay. &lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Results:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The optimized niosomal formulation demonstrated high stability, efficient dual-drug encapsulation, and a controlled release profile. Cytotoxicity studies showed that Tmx/Cur-loaded niosomes exhibited stronger inhibitory effects on MCF-7 cells compared to free drug solutions, while demonstrating low toxicity toward HEK-293 cells. The physicochemical characterization confirmed uniform particle morphology and favorable zeta potential values, supporting the stability of the prepared niosomes.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;These findings suggest that niosomal nanoparticles provide a promising carrier system for the co-delivery of tamoxifen and curcumin in breast cancer therapy, enhancing anticancer efficacy while minimizing adverse effects associated with conventional chemotherapy.&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Niosomal Nanoparticles</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Tamoxifen</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">curcumin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">breast cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Nanotechnology</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Drug encapsulation</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247498_bcbb1a2029581f421657c4f24e81f2ad.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Impact of ABCB1 Genetic Polymorphisms on Therapeutic Response and Safety of Atorvastatin in Iraqi Dyslipidemia Patients</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2061</FirstPage>
			<LastPage>2072</LastPage>
			<ELocationID EIdType="pii">247514</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2026.587212.2020</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Sarah Alaa</FirstName>
					<LastName>Fadhil</LastName>
<Affiliation>The Graduate Program of The Pharmacology and Toxicology Department, Pharmacy College, Kerbala University, Karbala, Iraq</Affiliation>
<Identifier Source="ORCID">0009-0009-5284-0400</Identifier>

</Author>
<Author>
					<FirstName>Noor D.</FirstName>
					<LastName>Aziz</LastName>
<Affiliation>Department of Clinical Pharmacy, Pharmacy College, Kerbala University, Karbala, Iraq</Affiliation>
<Identifier Source="ORCID">0000-0001-9795-0579</Identifier>

</Author>
<Author>
					<FirstName>Shaima</FirstName>
					<LastName>Jabbar</LastName>

						<AffiliationInfo>
						<Affiliation>Department of Pharmacology and Toxicology, Pharmacy College, Kerbala University, Karbala, Iraq</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Al-Subtain University, International Branch of Tehran University of Medical Sciences, Karbala, Iraq</Affiliation>
						</AffiliationInfo>
<Identifier Source="ORCID">0000-0002-3984-1822</Identifier>

</Author>
<Author>
					<FirstName>Riyadh Mustafa Murtadha</FirstName>
					<LastName>Al-Shehristani</LastName>
<Affiliation>College of Medicine, Al-Ameed University, Karbala, Iraq</Affiliation>
<Identifier Source="ORCID">0000-0001-6634-1906</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>05</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Inter-individual variability in response to atorvastatin may be influenced by genetic polymorphisms affecting drug transport. The ATP-binding cassette subfamily B member 1 &lt;em&gt;(&lt;/em&gt;&lt;/span&gt;&lt;em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;ABCB1&lt;/span&gt;&lt;/em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;)&lt;/em&gt; gene encodes P-glycoprotein, a transporter involved in the absorption, distribution, and elimination of atorvastatin. This study investigated the association of &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;ABCB1&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;rs1045642 (C3435T) and rs2032582 (G2677T) polymorphisms with atorvastatin efficacy and hepatic safety in Iraqi patients with dyslipidemia.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Materials and Methods:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;A cross-sectional study was conducted on 150 Iraqi patients with dyslipidemia receiving atorvastatin monotherapy (40 mg/day) for at least six months and 100 healthy controls. Lipid profile parameters and liver enzyme activities were measured using standard biochemical methods. Genotyping of rs1045642 and rs2032582 was performed using allele-specific polymerase chain reaction. Associations between genotypes, lipid parameters, liver enzymes, and treatment response were analyzed.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Results:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Patients with dyslipidemia exhibited significantly higher levels of triglycerides, VLDL-C, ALP, and AST, along with significantly lower HDL-C concentrations, compared with healthy controls (all &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt; 0.05). No significant associations were observed between rs1045642 genotypes and lipid profile parameters or achievement of the LDL-C treatment target. However, rs1045642 was significantly associated with ALT concentrations (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;= 0.0152). In contrast, rs2032582 was significantly associated with treatment response (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;P&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;= 0.0124), and carriers of the T allele were less likely to achieve the LDL-C target under the dominant genetic model (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;= 0.0175). Furthermore, rs2032582 was significantly associated with ALP levels (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;= 0.0432).&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;ABCB1&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;rs2032582 polymorphism was associated with atorvastatin treatment response, whereas rs1045642 showed no significant association with lipid-lowering efficacy. Both polymorphisms were associated with selected liver enzyme parameters, suggesting a potential role in atorvastatin disposition and hepatic handling. Further large-scale studies incorporating pharmacokinetic assessments are required to confirm these findings.&lt;/span&gt; &lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Atorvastatin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Dyslipidemia</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">ABCB1</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">pharmacogenetics</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">lipid profile</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">hepatotoxicity</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247514_492a25c906538a5ee56b2b4380cccb60.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Baneh Gum Essential Oil Enhances Doxorubicin Cytotoxicity and Downregulates hsa-mir-181a-5p in Human Gastric Adenocarcinoma Cells</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2073</FirstPage>
			<LastPage>2079</LastPage>
			<ELocationID EIdType="pii">247499</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.476590.1776</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Hossein</FirstName>
					<LastName>Rezashateri</LastName>
<Affiliation>Students Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Hadi</FirstName>
					<LastName>Esmaeili Gouvarchin Ghaleh</LastName>
<Affiliation>Applied Virology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-8562-2295</Identifier>

</Author>
<Author>
					<FirstName>Ebrahim</FirstName>
					<LastName>Salimi-Sabour</LastName>
<Affiliation>Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-5315-2126</Identifier>

</Author>
<Author>
					<FirstName>Mohammad</FirstName>
					<LastName>Amrollahi Sharifabadi</LastName>
<Affiliation>Department of Basic Sciences, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Maryam</FirstName>
					<LastName>Ghorbani</LastName>
<Affiliation>Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2024</Year>
					<Month>09</Month>
					<Day>02</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Current treatments for gastric cancer (GC) involve chemotherapy, radiotherapy, and surgery, with chemotherapy being the primary method despite its side effects and potential for drug resistance. Some plants are recognized as valuable sources for anticancer drug development, providing therapeutic benefits and reducing side effects economically. This study aims to investigate the anticancer effects of Baneh gum essential oil (BGEO) alone and in combination with doxorubicin on hsa-mir-181a-5p expression in AGS cells as a GC cell line, addressing the significant burden of late-diagnosed gastric cancer. &lt;/span&gt;&lt;br&gt;&lt;strong&gt;&lt;span class=&quot;fontstyle0&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span class=&quot;fontstyle2&quot;&gt;After culturing the AGS cells as a GC cell model, they were treated with different concentrations of BGEO (1, 2, 4, 6, 8, 10, 12, 14, and 16 &lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;μ&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;l) to determine the IC&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;sub&gt;50&lt;/sub&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;over a period of 72 hours, with the initial concentration held constant at 25 &lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;μ&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;g/ml. Subsequently, cell viability, apoptosis, and the expression of the hsa-mir-181a-5p gene were investigated alone and in combination with doxorubicin (0.025 &lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;μ&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;M). &lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Results:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Our results showed that treatment with BGEO causes a significant decrease in cell viability and a significant increase in the apoptosis of AGS cells compared to the control group (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;˂ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;0.05). Also, the results showed that the expression level of hsa-mir-181a-5p was significantly decreased in comparison to the control group (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;˂ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;0.05). The results of investigating the simultaneous effects of BGEO in combination with doxorubicin (DXR) showed that both agents in combination have more effects than single treatment (&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;p&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle4&quot;&gt;˂ &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;0.05). &lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;In summary, BGEO significantly reduces cell viability and increases apoptosis in AGS cells, suggesting its potential as a therapeutic agent. The notable decrease in hsa-mir-181a-5p expression indicates its influence on key regulatory pathways in GC. Additionally, this activity was enhanced in combination with DXR. These findings underscore the promise of BGEO in cancer treatment and call for further research into its mechanisms and clinical applications.&lt;/span&gt; &lt;br&gt;&lt;br&gt;&lt;br&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Gastric cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Baneh Gum Essential Oil</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cytotoxicity</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Apoptosis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">MicroRNA</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247499_bf1ad3dbce9dba2699d5f70e4e295bfb.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Baqiyatallah University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Applied Biotechnology Reports</JournalTitle>
				<Issn>2322-1186</Issn>
				<Volume>13</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>06</Month>
					<Day>30</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Cannabidiol Drives Efficient Neural Differentiation of Human Wharton’s Jelly Mesenchymal Stem Cells: A Small-Molecule Approach for In Vitro Neurogenesis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2080</FirstPage>
			<LastPage>2088</LastPage>
			<ELocationID EIdType="pii">247500</ELocationID>
			
<ELocationID EIdType="doi">10.30491/jabr.2025.540602.1903</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Erfan</FirstName>
					<LastName>Motalebzadeh</LastName>
<Affiliation>Department of Biology, Basic Science Faculty, Science and Research Branch, Islamic Azad University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-8865-0195</Identifier>

</Author>
<Author>
					<FirstName>Akram</FirstName>
					<LastName>Tajik</LastName>
<Affiliation>Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0009-0008-5863-6489</Identifier>

</Author>
<Author>
					<FirstName>Raheleh</FirstName>
					<LastName>Halabian</LastName>
<Affiliation>Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-3363-8276</Identifier>

</Author>
<Author>
					<FirstName>Nafiseh</FirstName>
					<LastName>Abbasabadi</LastName>
<Affiliation>Department of Biology, Science and Research branch, Islamic Azad University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Hanieh</FirstName>
					<LastName>Ahmadi</LastName>
<Affiliation>Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ali</FirstName>
					<LastName>Salimi</LastName>
<Affiliation>Tissue Engineering and Regenerative Medicine Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>08</Month>
					<Day>11</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;Over the past decade, research on small molecules such as cannabidiol (CBD) has expanded due to their ability to modulate biological pathways through protein interactions. Understanding how mesenchymal stem cells (MSCs) differentiate into neural-like cells is crucial for developing effective therapies for neurological disorders. This study aimed to investigate the efficacy of cannabidiol, as a cost-effective small-molecule inducer, in promoting the neural differentiation of human Wharton’s jelly MSCs (hWJ-MSCs) &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;in vitro &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;and to determine the optimal non-cytotoxic dose for this purpose.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Materials and Methods:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The optimal CBD dose (5 &lt;/span&gt;&lt;span class=&quot;fontstyle3&quot;&gt;μ&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;g/ml) was first determined using the MTT assay and acridine orange/ethidium bromide (AO/EB) staining. To evaluate neural differentiation potential, the expression of neural marker genes, &lt;em&gt;MAP-2,&lt;/em&gt; &lt;/span&gt;&lt;em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;NSE&lt;/span&gt;&lt;/em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;, Oligo-2,&lt;/em&gt; &lt;/span&gt;&lt;em&gt;&lt;span class=&quot;fontstyle4&quot;&gt;β&lt;/span&gt;&lt;/em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;-tubulin III&lt;/em&gt;&lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;,&lt;/em&gt; and &lt;/span&gt;&lt;em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;GFAP&lt;/span&gt;&lt;/em&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;,&lt;/em&gt; was assessed by real-time PCR at 7 and 14 days’ post-induction.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Results:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The results demonstrated significant upregulation of neural marker genes at 7 and 14 days after CBD treatment, confirming successful induction of neural differentiation.&lt;/span&gt;&lt;br&gt;&lt;span class=&quot;fontstyle0&quot;&gt;&lt;strong&gt;Conclusions:&lt;/strong&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;The designed protocol is highly effective and efficient for inducing neural differentiation. Further &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;&lt;em&gt;in vivo&lt;/em&gt; &lt;/span&gt;&lt;span class=&quot;fontstyle2&quot;&gt;studies using biocompatible scaffolds are necessary to elucidate the underlying mechanisms and therapeutic implications of these findings.&lt;/span&gt; &lt;br&gt;&lt;br&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Cannabidiol</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Small molecules</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Wharton's Jelly mesenchymal stem cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Neural-like Cells</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.biotechrep.ir/article_247500_12f9a054d1be54605209b959cfbe0d58.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
